#side-effects

10 articles tagged #side-effects.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

#2026 4 #503a 1 #503b 2 #alcohol 1 #alternatives 1 #ban 1 #before-and-after 1 #beginners 2 #berberine 1 #brand-name 3 #bridge-program 1 #cagrilintide 1 #cagrisema 1 #clinical-research 1 #clinical-trials 1 #comparison 2 #compounded 8 #compounded-glp1 1 #compounded-semaglutide 1 #compounded-tirzepatide 1 #compounding-ban 1 #copay 1 #cost 13 #coupon 1 #coverage 1 #diabetes 1 #diet 1 #dosage 1 #eli-lilly 3 #enforcement 1 #enrollment 1 #fact-check 2 #fda 4 #fda-approval 1 #flat-rate 1 #foundayo 7 #framework 1 #glp-1-patches 1 #glucose-monitors 1 #guide 1 #hhs 1 #hims 1 #how-to-get 1 #injectable 7 #injection 1 #insulin-resistance 1 #insurance 11 #ivy-rx 1 #ivyrx 1 #legality 1 #liraglutide 1 #medicaid 1 #medicare 5 #mounjaro 6 #natures-ozempic 1 #news 2 #novo-nordisk 2 #online-prescription 1 #oral-glp1 6 #oral-semaglutide 1 #orforglipron 4 #ozempic 9 #pcos 1 #personalized-treatment 1 #pill 1 #pipeline 1 #policy 1 #precision-medicine 1 #prior-authorization 2 #regulation 2 #results 1 #rfk 1 #ro 2 #safety 5 #savings-card 1 #schedule 1 #semaglutide 24 #serena-williams 1 #shortage 1 #side-effects 10 #storage 1 #supplements 2 #surmount 2 #surmount-5 1 #telehealth 1 #telehealth-enforcement 1 #telehealth-review 1 #timeline 1 #tirzepatide 22 #travel 1 #tsa 1 #type-2-diabetes 1 #wada 1 #warning-letters 1 #wegovy 17 #wegovy-hd 1 #wegovy-pill 3 #weight-loss 26 #weight-loss-plateau 1 #without-insurance 1 #zepbound 18

Editorial still-life illustrating retatrutide, a Phase 3 triple-agonist weight loss drug

Analysis News & PipelineAugust 5, 2026• 11 min read

Retatrutide TRIUMPH-1 Results (May 2026): 30.3% Weight Loss, Phase 3 Primary Trial

Updated August 5, 2026: Added Lilly's ClinicalTrials.gov expanded-access record (NCT07629401), registered June 5, 2026, which lists no eligibility criteria. Biologic classification lawsuit context (Lilly v. FDA, Case 1:24-cv-01503). Obesity (TRIUMPH-1): 28.3% weight loss at 80 weeks, 30.3% at 104 weeks, 65.3% achieved BMI <30. T2D (TRANSCEND-T2D-1): A1C −2.0%, weight −16.8%. NDA expected Q4 2026. Court ruling: FDA's bright-line classification of retatrutide as a drug (not biologic) vacated. Outcome determines whether compounding can legally exist post-approval.

An empty stemmed glass resting upside down on a linen napkin beside a full glass of water on a weathered oak table, morning light through sheer curtains

Guide Side Effects & SafetyAugust 2, 2026• 9 min read

Alcohol and GLP-1 Medications: Risks, Cravings, and What the Labels Leave Out

Neither the Wegovy nor the Zepbound prescribing information mentions alcohol. This is what the labels do say about hypoglycemia and nausea, what the craving research has and has not shown, and what changes if you also take insulin or a sulfonylurea.

Editorial still-life illustrating a comparison of Wegovy and Zepbound for weight loss

Analysis ComparisonsJuly 7, 2026• 14 min read

Wegovy vs Zepbound (June 2026): SURMOUNT-5 Head-to-Head, Wegovy HD, & Cost Comparison

Updated August 2026: SURMOUNT-5 head-to-head trial (NEJM): Zepbound 20.2% vs Wegovy 13.7% weight loss at 72 weeks. Wegovy HD (7.2mg, FDA-approved March 2026) closes the gap at 20.7%. NovoCare lists the Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and pill from $149/mo, prescription required and dose-dependent; LillyDirect lists Zepbound from $299/mo with higher-dose pricing. Both may be as low as $25/mo for eligible commercially insured patients using a savings card.

Editorial lifestyle photograph illustrating a guide to Foundayo orforglipron oral GLP-1

Guide GuidesApril 29, 2026• 14 min read

Foundayo (Orforglipron) Guide 2026: from $149/mo Self-Pay, 12.4% Weight Loss, No Fasting Required

Updated August 14, 2026: Foundayo (orforglipron) is Lilly's FDA-approved non-peptide GLP-1 pill. LillyDirect self-pay is $149 at 0.8 mg, $199 at 2.5 mg, $299 at 5.5 or 9 mg, and $299 at 14.5 or 17.2 mg with a refill within 45 days, otherwise $349. No fasting is required.

Editorial lifestyle still-life accompanying a guide to Zepbound side effects and management

Guide Side Effects & SafetyApril 20, 2026• 10 min read

Zepbound Side Effects (2026): Nausea 29%, Diarrhea 23%, Vomiting 13%, Full Guide with SURMOUNT Trial Data

Verified July 2026: Zepbound (tirzepatide) side effects from the SURMOUNT clinical trials, nausea affects 24-29% of patients (vs 8% placebo), diarrhea 19-23%, vomiting 8-13%. Only 4.3% discontinued at the highest dose. GI symptoms peak during dose escalation and resolve within 4-8 weeks for most patients. Full breakdown by dose, timeline, management strategies, and when to call your doctor.

Editorial lifestyle photograph illustrating a beginner guide to GLP-1 weight loss medications

Guide GuidesApril 13, 2026• 12 min read

GLP-1 Receptor Agonists for Weight Loss 2026: FDA-Approved Options, Cost & Prescription Guide

FDA-approved GLP-1 receptor agonists for weight loss, 2026 guide. Eligibility: BMI 30+ (or 27+ with comorbidity). Semaglutide produces 14.9% weight loss (STEP-1), tirzepatide 20.9% (SURMOUNT-1). Cost: $25-$349/mo via telehealth. Complete 5-step prescription process with verified provider pricing. Options: Foundayo (orforglipron), oral Wegovy, Zepbound, and injectable semaglutide.

Editorial photograph illustrating what to expect during the first month on a GLP-1 medication

Guide GuidesApril 11, 2026• 8 min read

First Month on GLP-1 (2026): 2-5 lbs Lost Week 1-4, Nausea Peaks Week 4, Week-by-Week

Verified July 2026: GLP-1 patients lose 2-5 pounds in their first month. Appetite suppression starts week 1-2. Nausea peaks at week 4 dose escalation. 98.1% of GI side effects are mild-to-moderate per STEP-1 and SURMOUNT-1 trials. Complete week-by-week timeline with dosing schedule.

Editorial lifestyle photograph illustrating foods to avoid while taking GLP-1 medications

Guide Side Effects & SafetyApril 11, 2026• 10 min read

Foods to Avoid on GLP-1 (2026): 7 Worst Offenders + What to Eat Instead

Verified July 2026: The 7 worst foods on Ozempic, Wegovy, Zepbound, fried food, sugary drinks, red meat portions, raw cruciferous veg, carbonated beverages, alcohol, high-fiber bars. GLP-1s slow gastric emptying 25-40%, triggering nausea in 44% of patients. Full list with alternatives.

Editorial still-life illustrating a guide to GLP-1 side effects and management

Guide Side Effects & SafetyApril 11, 2026• 12 min read

GLP-1 Side Effects (2026): Nausea 44%, Diarrhea 30%, Vomiting 24%, Complete Management Guide

Verified July 2026: 44% of Wegovy patients report nausea, 30% diarrhea, 24% vomiting in STEP-1 trial. Only 7% discontinued for side effects. Tirzepatide (Zepbound) is more tolerable: 24-33% nausea, 7-13% vomiting per SURMOUNT-1. Full management guide with red flags.

Editorial still-life illustrating the FDA approval of Foundayo orforglipron oral GLP-1

News News & PipelineApril 2, 2026• 10 min read

Foundayo (Orforglipron) FDA Approved: The First GLP-1 Weight Loss Pill You Can Take Anytime

The FDA just approved Eli Lilly's Foundayo (orforglipron), the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.